The US Food and Drug Administration (FDA) has approved a fifth vaccine to guard against the 2009 H1N1 influenza virus.

The most recent vaccine is manufactured by Canada’s ID Biomedical, a division of GlaxoSmithKline, and is based on the same egg-based manufacturing process used to produce seasonal flu vaccines.

Like the seasonal flu vaccine, this H1N1 vaccine is expected to have mild side effects, the most common being soreness at the injection site as well as mild fever and body aches and fatigue for a few days after the inoculation.

The FDA is collaborating with other government agencies to enhance adverse event safety monitoring during and after the H1N1 2009 vaccination programme.